Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL815991 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814745 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814393 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL815987 | 1.00 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814768 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814847 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL815134 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL813746 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL814766 | 0.91 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 | |
| SCHEMBL17584890 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1978961-B1 | TETRALONE-BASED MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-8053603-B2 | Tetralone-based monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-8053603-B2 | Tetralone-based monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2011-11-08 | — | — | US | disclosed |
| WO-2007081542-A9 | TETRALONE-BASED MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007081542-A2 | TETRALONE-BASED MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197588-A1 | Tetralone-based monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.